[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

20211,017 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet

Volume 397, Issue 10276, pp. 797-804

Field-Weighted Citation Impact: 110.11